Maxwell Biosciences

Focus: Maxwell Biosciences is a public biotech company founded in 2016 focused on antivirals with emerging programs in infectious diseases and neurology, headquartered in Austin, TX. The company operates at a pre-revenue or early-stage clinical phase with minimal commercial traction.

Infectious Diseases Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$20M

Open Jobs

About Maxwell Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Maxwell Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients

Alzheimer Disease

N/A

Clinical Trials (1)

NCT06079827Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients

N/A

Help build intelligence for Maxwell Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage biotech with public status offers equity upside potential and career growth in emerging therapeutic areas including infectious diseases and neurology
Austin headquarters provides access to growing biotech hub with lower cost-of-living than major pharma centers
Diversified pipeline across atrial fibrillation, sensory dysfunction, Alzheimer's disease, and Long COVID positions company in high-unmet-need spaces

Watch Out For

Severely limited hiring activity (1 active role) signals organizational constraint, minimal growth, or restructuring phase
No commercial products, published data (0 publications), or clearly defined clinical development phases suggest early-stage execution risk and extended pre-revenue timeline
Missing financial data, employee count, and H1B sponsorship details create visibility gaps about company stability and career trajectory clarity

Generated by Claude from Maxwell Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Sensory Processing Difficulties in Adults and Adolescents

Sensory Processing Dysfunction

N/A

RNA Biomarker Blood Test

Long COVID

N/A

Clinical Trials (1)

NCT06311435Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

N/A

Spatial Resynchronization Therapy delivered by the MAX-SRS, external recording and stimulation device

Atrial Fibrillation

N/A